INTS
Intensity Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.11
+2.75%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +32.4%
- EBIT
- +10.8%
- EPS
- +76.4%
- Free cash flow
- +19.2%
- Operating cash flow
- +19.2%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +40.8%
Three-year CAGR
- Revenue
- —
- EBITDA
- +28.7%
- EBIT
- +27.8%
- Net income
- +28.7%
- EPS
- +70.7%
- Free cash flow
- +39.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026